Odds
Yes70%
Range contracts
Exactly one range settles YES.
Range
Chance
Yes
No
$0–$100
50%
$100–$200
50%
$200–$300
50%
$300–$400
50%
$400–$500
50%
$500–$600
50%
$600–$700
70%
$700–$800
50%
$800–$900
50%
$900–$1,000
50%
$1,000–$1,100
50%
$1,000–$1,100
50%
$1,100–$1,200
50%
$1,200–$1,300
50%
$1,300–$1,400
50%
$1,400–$1,500
50%
$1,500–$1,600
50%
$1,600–$1,700
50%
$1,700–$1,800
50%
$1,800–$1,900
50%
$1,900–$2,000
50%
≥ $2,000
50%
Market details
Status
open
Positions
1
Volume
50 cr
Locks
Mar 27, 2026
Updated
Jan 30, 2026, 01:56 AM
Rules summary
Resolves YES if the initial U.S. wholesale acquisition cost (WAC) at launch for ET-600 (desmopressin oral solution) is ≥ $1,000/month, using the first publicly available WAC from a sponsor price announcement or a pricing compendium (e.g., Red Book / Medi-Span).
If ET-600 (desmopressin oral solution) does not have an FDA approval for Central diabetes insipidus / AVP-D (as described by sponsor) on or before 2026-03-27, resolves NO.
Reference: https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-fda-acceptance-new-drug-1
Range: $600-$700.
Market context
Launch-WAC market anchored to $1,000/month. Evaluation date: 2026-03-27. Source: https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-fda-acceptance-new-drug-1
People are also buying
BrowseVote on range
Community vote80% Yes · 5 votes
Vote